Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Abbott Will Split Into Two Companies

by Michael McCoy
October 24, 2011 | A version of this story appeared in Volume 89, Issue 43

Abandoning its structure as a diversified health care company, Abbott Laboratories will split into separate medical products and research-based drug companies. The medical products company will have annual sales of about $22 billion. It will include Abbott’s nutritional products, diagnostics, medical devices, and branded-generics businesses and will retain the Abbott name. The pharmaceutical firm, to be named later, will have annual sales of about $18 billion. Leading products will include Humira, Lupron, Synagis, Kaletra, Creon, and Synthroid.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.